Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank
March 04, 2019 13:17 ET
|
NANOBIOTIX
Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank Proceeds strengthen balance sheet and cash visibilityPayment...
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
February 05, 2019 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Nanobiotix envisage de procéder à une offre au public aux Etats-Unis
January 16, 2019 13:05 ET
|
NANOBIOTIX
Nanobiotix envisage de procéder à une offre au public aux Etats-Unis Paris, France, et Cambridge, Massachusetts (USA) le 16 janvier 2019 – NANOBIOTIX SA (Euronext: NANO – ISIN: FR0011341205),...
Nanobiotix Plans to Conduct Registered Public Offering in the United States
January 16, 2019 13:05 ET
|
NANOBIOTIX
Nanobiotix Plans to Conduct Registered Public Offering in the United States Paris, France and Cambridge, Massachusetts (USA), January 16, 2019 – NANOBIOTIX SA (Euronext : NANO – ISIN :...
Nanobiotix et le MD Anderson Cancer Center annoncent une collaboration clinique globale de grande envergure portant sur NBTXR3
January 07, 2019 14:09 ET
|
NANOBIOTIX
La collaboration comporte dans un premier temps neuf nouveaux essais cliniques de phase I/II avec NBTXR3, premier produit d’une nouvelle classe de Nanobiotix, dans six types de cancer différents -...
Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
January 07, 2019 14:09 ET
|
NANOBIOTIX
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types - head and neck, pancreatic, thoracic, lung,...
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
December 20, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
December 17, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
December 06, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
December 04, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...